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  Shear stress, anti-fouling coatings, blood coagulation, zwitterionic polymers, 
fibrinogen fouling. 
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Blood-contacting devices coated with anti-clotting materials would typically fail 
due to clot formation after about 2 weeks of exposure to blood flow. Our overarching 
hypothesis for their short-term success is that the failure modes of these anti-clotting 
coatings are either due to 1) a slowed-pace procoagulant protein fouling, 2) their 
erosion due to shear stress, or 3) a combination of both. This study however partly tests 
the hypothesis by evaluating the effect of shear stress on coating stability. This was 
done by exposing DOPA-PCB-300/dopamine coated polydimethylsiloxane (PDMS) to 
physiological shear stresses using a recirculation system which consisted of dual 
chamber acrylic flow cells, tygon tubing, flow probe and meter, and perfusion pumps. 
The effect of shear stress induced by phosphate buffered saline flow on coating stability 
was characterized with differences in fibrinogen adsorption between control (coated 
PDMS not loaded with shear stress) and coated samples loaded with various shear 
stresses. Fibrinogen adsorption data showed that relative adsorption on coated PDMS 
that weren’t exposed to shear (5.73% ± 1.97%) was significantly lower than uncoated 
PDMS (100%, p < 0.001). Furthermore, this fouling level, although lower, was not 
significantly different from coated PDMS membranes that were exposed to 1 2 
(9.55% ± 0.09%, p = 0.23), 6 2 (15.92% ± 10.88%, p = 0.14), and 10 
2 (21.62% ± 13.68%, p = 0.08). Our results show that DOPA-PCB-
300/dopamine coating are stable, with minimal erosion, under shear stresses tested. 
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Large quantities of blood-contacting medical devices are used annually world-wide.1, 2 It 
is estimated that more than 200 million of these devices are utilized in patients in the 
U.S alone. 3 They range from devices with small surface areas like catheters, vascular 
grafts, heart valves, cannulas, glucose, lactate sensors, and stents to those with 
moderate surface areas like pacemakers, artificial kidneys, and left ventricular assist 
devices. Then there are those with relatively larger surface areas like the artificial lungs, 
artificial hearts, and extracorporeal membrane oxygenation circuits. 
The surfaces of these devices are made up of artificial materials that are different 
from endothelial cell surfaces, which interface with flowing blood.4−6 These cells express 
enzymes and secrete nitric oxide that maintain blood tone.7−10 Without these properties, 
blood rapidly activates into clots upon contact with artificial materials.11, 12 For blood-
contacting devices, clot formation can cause cessation of blood flow and lead to device 
failure13−15. Moreover, devices that do not fail may release clots into systemic circulation 
and cause embolic complications.14, 16−18 In life support devices these clots can result in 
morbidity and mortality. For instance, a small bore vascular graft serving as a coronary 
artery may occlude from formation and cause myocardial infarction (heart attack). With 
artificial lungs, clotting is especially problematic as they have relatively large surface 
areas (1.3-2 2) and a period of usage lasting from several weeks to months however 
they typically fail after 7-14 days with accompanying hemorrhagic complications.13−15,18 
Catheters, on the other hand, have a limited lifespan and do not reliably allow repeated 
sampling of blood or continuous pressure monitoring in patients as their small lumen 
diameters make them more prone to failure by clots19−22.  
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Current approaches for controlling biomaterial-induced clot formation have been 
largely inadequate. Commercial coatings have only shown moderate inhibition of clot 
formation in short-term studies23−32 and are not sufficient to allow large decreases in 
systemic anticoagulation. The most successful approach to date has been to chemically 
immobilize heparin on blood-contacting surfaces to reduce thrombosis and lower 
anticoagulant administration.33,34 Although this approach has been widely adopted, 
major limitations persist because the surface-bound heparin leaches, resulting in a 
progressive loss of anticoagulation activity.35,36 Other hydrophilic coatings including 
PHISIO (Sorin) 39, Trillium (Medtronic) 40, poly-2-methoxyethyl acrylate (PMEA) 
polymer41 and sulfobetaine42 that have undergone extensive human clinical evaluation 
have shown no drastic non-thrombogenic benefit compared to existing heparin-coated 
materials.43,44
Systemic anticoagulants hence remain the adjunctive therapy of choice 
although they pose an increased risk of bleeding complications. 45−47  
Important factors that affect the efficiency these coatings include their stability 
and coverage on devices and mechanism(s) of inhibiting coagulation. Coatings that 
become unstable and erode against fluid shear progressively lose their anticoagulation 
activity and imperfections in coating can weaken the anti-coagulation effectiveness, as 
procoagulant proteins can adsorb at uncoated spots. Our overall hypothesis for their 
short-term success is that the failure modes of these anti-clotting coatings are either 
due to 1) a slowed-pace procoagulant protein fouling, 2) their erosion due to shear 
stress, or 3) a combination of both.  To test our hypothesis, a relatively new coating 
material that has shown ultra-low auto-adsorption of pro-coagulant proteins, 
polycarboxybetaine,48-50 was used to study the effect of shear stress on coating stability. 
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PDMS coated with DOPA-PCB-300/dopamine were exposed to shear stresses similar 
to those found in the vena cava, large veins, and conduit arteries.51 
#

	
		 The dual chamber flow cell and 
recirculation system design is shown in 	
$. It consists of an acrylic (Custom 
Creative Plastics, FL) flow cell that was designed using Autodesk inventor (San Rafael, 
CA), a 3/16” I.D. and 5/16” O.D. tygon tubing circuit (Fisher Scientific, MA), a pump 
(Stöckert Shirley multiflow roller blood perfusion pump, SOMA Tech. Bloomfield, CT), 
Transonic flow probe and meter (Transonic Inc. Cambridge MA) and Leuer lock priming 
ports. The flow cell assembly of top and bottom mates
measures Length = 11.43 , 
width = 5.87 , height = 1.60 . and are attached to a recirculation circuit using 
polycarbonate connectors (Qosina, NY)%
The flow cell chamber measures a 1 cm x 6.35 
 x 0.5  with a hydraulic diameter = 0.67 , entrance area = 0.37 2. Test 
samples (surface modified or unmodified), represented by the rectangular piece inside 
the flow cell, are first affixed onto the bottom mate’s  flow chamber already lined with an 
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adhesive nitrile sponge rubber gasket (Grainger.com, Lake Forest, IL) followed by the 
application of a gasket-lined top mate and compression of top and bottom mates with 
screws.
			
	 To ensure no 
leakages during application of flows over samples, a leak test was performed under 
experimental test conditions. A PDMS sample measuring 8.89  x 2.54  was 
inserted into the recirculation circuit and primed with 35mL of phosphate buffered saline 
(PBS) ensuring that no air bubbles were present in the circuit before flow initiation. 
Recirculation was maintained for 8 hours at low flow (30 ) and high flow (1500 
). Since the blood perfusion pumps used in this experiment are roller pumps that 
display only digital revolutions per minute (rpm) readouts, it was necessary to determine 
their flow rates as a function of rpms. First, their tubing occlusion were set at the 
recommended clinical pump occlusion setting where a 100cm fluid column drops 
25cm/min52-53. At this occlusion setting, a calibration curve of rpm versus flow rates was 
generated by pumping of PBS from a reservoir to an empty container. Rpms were set at 
50, 100, and 150 and the pumped volume and pumping time recorded. An rpm to flow 
rate calibration curve was generated for each pump so that a relation of wall shear 
stress as a function average flow velocity (flow rate/cross sectional area), fluid dynamic 
viscosity, and hydraulic diameter of flow chamber could be developed. 
Wall shear stress was calculated as 
 = ( × 	
)& where
 Wall shear stress (), 
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 Darcy-Wiesbach friction factor for the acrylic chamber surface is  = 	  since flow is laminar,
 Reynolds number, 
  Density of fluid (	), 
	
 =	 	 !"#	$%&'	()*$+",	
().
The entrance length, -& was expressed in terms of Reynolds number and hydraulic
diameter as - = .. .	 × 	 × 01 where 01 is the hydraulic diameter of the flow
chamber given as 
×23
(451)& where 23 is cross sectional area and  and  are width and
height of the chamber entrance. The entrance length was calculated to be 0.04  
using 01
= 0.67  and		~	1.
	 !"#$#%&&'
		
	(
	PDMS membrane (NuSil Tech. CA) measuring 8.89  x 2.54  
were casted via two-part polymerization process. Cured PDMS membranes were 
coated with DOPApCB-300 using a dip-coating process previously described.50 Briefly, 
PDMS was immersed in TRIS buffer (pH 8.5) containing dissolved 2.8  DOPA-
PCB-300/dopamine mixture at a ratio of 1:40. Buffer with PDMS was gently agitated for 
2hrs. A schematic of the coating process is presented in 	
'. 
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Uncoated (N=5 samples at stagnant, no flow) and coated membranes (N=5 
samples/test condition) were inserted into flow cells (	
()) and the circuits were 
primed with phosphate buffered saline, pH= 7, (Sigma Aldrich, MO). Flows were 
initiated at 60 , 150  and 230  and recirculated through the flow 
cells for 8 hours. For each run, a set of four test conditions (coated PDMS with 0, 1, 6, 
and 10 2) were evaluated followed by test runs for uncoated no flow samples.  
These flows yield physiologically relevant shear stress of 1 2, 6 2 and 
10 2. The membranes were carefully removed after recirculation and stored in 
PBS. Three 1  x 1  pieces from each sample were sectioned and prepared for 
standard fibrinogen adsorption ELISA as previously described.50 The circuits were 
soaked in 10% bleach overnight, rinsed with DI water and dried with pressurized 
nitrogen between test runs. 
 Briefly, the 1  x 1 squares were placed into a 24-
well plate and incubated in 1  of 1 fibrinogen for 90 minutes at room 
temperature. The disks are then washed five times with PBS and incubated with 1mL of 
1 mg/mL BSA (Sigma Aldrich) for 90 minutes at room temperature. The samples were 
again washed five times with PBS. Next, the samples were transferred into new wells 
and incubated in 1:1000 dilution of HRP (Sigma Aldrich) anti fibrinogen in PBS for 30 
minutes, followed by another wash in PBS. The samples were then transferred to a new 
set of wells. The solution is then incubated in 500 uL of 1  OPD (Sigma Aldrich) 
in 0.1 M citrate-phosphate buffer containing 0.03% hydrogen peroxide. This reaction 
was then quenched after 30 minutes by the addition of 500  of 1N HCL (Sigma 
Aldrich). The supernatant was then removed from each sample and transferred into 
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cuvettes. The absorbance of each supernatant was then measured at 492  using 
UV-vis spectrophotometer (Beckman Coulter, CT).  It was expected that uncoated 
PDMS samples would have higher absorption of fibrinogen and thus higher UV-vis 
absorbance levels. The effect of coating erosion on biocompatibility was determined as 
the percent increase in fibrinogen adsorption compared to appropriate DOPAPCB-
300/dopamine coated PDMS controls. Less than 10% increment was considered highly 
stable, between 10 – 30% increase was considered stable and 30% or greater was 
considered unstable.  
"	( A single factor ANOVA (SPSS, Chicago IL) was run to determine 
statistical differences between controls (uncoated PDMS, and DOPApCB-300/dopamine 
coated PDMS with no flow) and coated PDMS exposed to 1 2, 6 2 
and 10 2 shear stresses. A < 0.05 was regarded as significant. 


*

)

The exploded view of the flow cell design showing top and bottom mates, cell chamber, 
gasket channel circuit connectors are shown in 	
(! and 	
(+

( are 
the flow cell and recirculation circuit prototypes. There were also no observable leaks or 
air bubbles in the circuit during all runs. The 5  syringe in Figure 3C was used to 
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prime and extract trapped bubbles during priming. 
As presented in 	
,, the rpm to flow rate calibration of pumps showed linear 
relationships between the two variables although there were some pump-pump variation 
indicated by the rpm-to-pump data fitting equations. The coefficient of determination, R2, 
for pumps 1, 2, 3 and 4 were 0.99, 1, 0.99, and 0.99 respectively. 
Each pump’s rpm-to-flow rate output provided guidance to obtain desired flow rates. 
Knowing the flow rates and obtaining the average flow velocity by dividing flow rates by 
the cross-sectional area of the cell chamber, sample or wall shear stress could be 
calculated using the  equation from the methods section. 	
- shows the wall
shear stress on the primary axis as a function of flow rate and Reynolds number on the 
secondary axis as a function of flow rate. After fitting calculated shear stress to flow rate 
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
date, it was determined that the calculated wall shear,, increased with flow rate
according to  = .. .	 89:;<	×	=>;3=	×	=- ?	× 	 8
=-
=>;? @ 	A @ BC	(
9:;<
3= ). In the shear stress
calculation, the Darcy-Wiesbach friction factor depended on only the Reynolds number 
since the pre-calculated Reynolds number was < 2300. Shown also in 	
-, we see 
that the Reynolds numbers calculated from the experimental flow rates and fluid 
properties were low and ranged from 0.25 – 1.25. 
Although the Reynolds numbers were low, a comparison of flow entrance length 
to cell chamber length was made to determine whether turbulent flow effects typical at 
flow entrances were dominant over entire length.  The calculated entrance length, -,
was 0.04  and compared to the cell chamber length = 6.35 which is a two orders 
of magnitude bigger indicating that almost the entire sample surface and therefore the 
cell chambers saw fully developed laminar flows. Because the wall shear stress,,
remains constant along the flow direction in the fully developed regions of both turbulent 
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or laminar flows, it was also deduced that almost all of the sample surface area saw 
constant non-zero shear stresses during flow. However, in the entrance regionisn’t
constant butrather starts out larger before decreasing to a constant stress in the fully 
developed region for any given flow rate. Therefore flow-induced erosion of DOPA-
PCB-300/dopamine may be possible and perhaps higher in the entrance length region 
than what may occur in the fully developed flow region. It should be noted that the 
scenario described above only reflects shear stress dynamics in a single fluid flow pass 
while the continued interaction between the velocity profile and the samples from 
multiple passes may further influence coating stability. Subsequent passes may cause 
repeated interferences of the fully developed flow profile at the tubing/flow cell 
connection and lead to repeated and transient increases in shear stress in the entrance 
length region which may further influence the stability of the coating especially in high 
shear stress test conditions. This theory is supported by the fibrinogen adsorption data 
from coated samples that were exposed to shear stresses.  Fibrinogen fouling before 
flows on DOPA-PCB-300/dopamine coated PDMS (5.73 ± 1.97%) was significantly 
lower than uncoated PDMS (100%, p < 0.001) as shown in 	
.. The data shows 
that fibrinogen fouling on coated samples increase with increasing shear stress 
although to levels not significantly different from control (coated samples not loaded with 
shear stress). In addition, fouling on coated PDMS with zero shear stress, although 
lower, was not significantly different from coated samples that were exposed to 1 
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dynes/cm2 (9.55% ± 0.09%, p = 0.23), 6 dynes/cm2 (15.92% ± 10.88%, p = 0.14), and 
10 2 (21.62% ± 13.68%, p = 0.08). Our findings show that DOPApCB-
300/dopamine coating were stable under the test conditions and only minimal coating 
erosion was observed. Compared to the coated PDMS no shear stress case, coated 
surfaces that were exposed to 1, 6, and 10 2 of shear stress, adsorbed 3.83%, 
10.20%, and 15.90% more fibrinogen respectively. It should be noted that the 
experiment was conducted at room temperature and with pH 7 PBS which are different 
from in-vivo conditions where the surface will interact with blood flow at a higher 
temperature. The study design used here however allows for a direct measurement of 
nonspecific protein adsorption on coated model surfaces after they have been exposed 
to flow, allowing for quantification of the stability of any non-fouling coating or surface 
immobilized enzymes against shear stress. Contamination of sample surfaces with 
biological material from stability testing with whole blood and perhaps plasma, on the 
Page 13 of 18 Langmuir
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

other hand, could lead to unreliable coating stability data using this approach. Non-
specific protein fouling on coatings exposed to blood or plasma flow shear stress would 
be simply difficult to evaluate. 


In this study, the stability of a low-fouling DOPA-PCB-300/dopamine coating against 
various flow-induced shear stresses was measured. It was found that instability, as 
measured by percent increase in fibrinogen fouling between shear treated and no shear 
samples, increases with shear stress. To conduct the experiment, flow cells were 
fabricated and characterized for flows that yield different shear stresses (1 2, 6 
2, and 10 2). The surfaces of PDMS membranes were then coated 
with low fouling DOPA-PCB-300/dopamine followed by testing of the coating’s stability 
against those shear stresses by placing the coated PDMS samples inside the flow cells 
and recirculating PBS over the samples at given flow rates for 8 hrs. Fibrinogen fouling 
between shear stress and no shear stress coated samples were compared to determine 
differences. Less than 10% increment was considered highly stable, between 10 – 30% 
increase was considered stable and 30% or greater was considered unstable. 
Compared to the coated PDMS with no shear stress case, coated surfaces that were 
exposed to 1, 6, and 10 2 of shear stress, respectively adsorbed 3.83%, 
10.20%, and 15.90% more fibrinogen. Our results therefore show that DOPApCB-
300/dopamine coating were stable and only minimal coating erosion was observed. As 
newer and more robust anticlotting coatings get developed, this simple and easy-to-use 
in-vitro flow cell system provides an appropriate pre-in vivo screening tool for 
determining coating stability under flow before conducting animal testing. The flow 
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
system can be used to evaluate many coatings and surface modifications in 
biomaterials and blood-contacting devices. Other biomarkers for blood coagulation can 
be studied with this flow cell as well as evaluating the effects of pH and temperature. . 
The gas transfer properties of polymeric materials and interrogation of human cells and 
microorganisms such as bacteria and viruses with polymer permeable agents like nitric 
oxide could also be studied taking advantage of the dual chamber design of the flow 
cell. The results here suggest that coating erosion play a role in reducing the 
effectiveness of anti-fouling coatings used on blood-contacting medical devices. 
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